COMPAGNIE CHARGEURS INVEST (CRI.PA) Fundamental Analysis & Valuation

EPA:CRI • FR0000130692

Current stock price

8.44 EUR
-0.22 (-2.54%)
Last:

This CRI.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CRI.PA Profitability Analysis

1.1 Basic Checks

  • CRI had negative earnings in the past year.
  • In the past year CRI had a positive cash flow from operations.
  • In multiple years CRI reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: CRI reported negative operating cash flow in multiple years.
CRI.PA Yearly Net Income VS EBIT VS OCF VS FCFCRI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M 60M

1.2 Ratios

  • CRI's Return On Assets of -2.49% is on the low side compared to the rest of the industry. CRI is outperformed by 66.67% of its industry peers.
  • The Return On Equity of CRI (-9.87%) is worse than 66.67% of its industry peers.
  • The Return On Invested Capital of CRI (0.26%) is worse than 66.67% of its industry peers.
  • CRI had an Average Return On Invested Capital over the past 3 years of 2.15%. This is below the industry average of 6.85%.
Industry RankSector Rank
ROA -2.49%
ROE -9.87%
ROIC 0.26%
ROA(3y)-0.61%
ROA(5y)0.79%
ROE(3y)-2.6%
ROE(5y)2.31%
ROIC(3y)2.15%
ROIC(5y)3.55%
CRI.PA Yearly ROA, ROE, ROICCRI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15

1.3 Margins

  • CRI has a worse Operating Margin (0.64%) than 66.67% of its industry peers.
  • CRI's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 29.62%, CRI is doing worse than 73.33% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CRI has grown nicely.
Industry RankSector Rank
OM 0.64%
PM (TTM) N/A
GM 29.62%
OM growth 3Y-54%
OM growth 5Y-40.23%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.99%
GM growth 5Y2.14%
CRI.PA Yearly Profit, Operating, Gross MarginsCRI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CRI.PA Health Analysis

2.1 Basic Checks

  • CRI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for CRI remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, CRI has more shares outstanding
  • CRI has a worse debt/assets ratio than last year.
CRI.PA Yearly Shares OutstandingCRI.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
CRI.PA Yearly Total Debt VS Total AssetsCRI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • CRI has an Altman-Z score of 0.98. This is a bad value and indicates that CRI is not financially healthy and even has some risk of bankruptcy.
  • CRI has a Altman-Z score of 0.98. This is amonst the worse of the industry: CRI underperforms 80.00% of its industry peers.
  • A Debt/Equity ratio of 1.56 is on the high side and indicates that CRI has dependencies on debt financing.
  • With a Debt to Equity ratio value of 1.56, CRI is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.56
Debt/FCF N/A
Altman-Z 0.98
ROIC/WACC0.04
WACC6.29%
CRI.PA Yearly LT Debt VS Equity VS FCFCRI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • CRI has a Current Ratio of 2.42. This indicates that CRI is financially healthy and has no problem in meeting its short term obligations.
  • CRI has a Current ratio of 2.42. This is amongst the best in the industry. CRI outperforms 93.33% of its industry peers.
  • A Quick Ratio of 2.07 indicates that CRI has no problem at all paying its short term obligations.
  • CRI has a better Quick ratio (2.07) than 93.33% of its industry peers.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2.07
CRI.PA Yearly Current Assets VS Current LiabilitesCRI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CRI.PA Growth Analysis

3.1 Past

  • The earnings per share for CRI have decreased strongly by -431.47% in the last year.
  • Looking at the last year, CRI shows a decrease in Revenue. The Revenue has decreased by -2.94% in the last year.
  • CRI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -12.58% yearly.
EPS 1Y (TTM)-431.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-247.73%
Revenue 1Y (TTM)-2.94%
Revenue growth 3Y-17%
Revenue growth 5Y-12.58%
Sales Q2Q%-18.24%

3.2 Future

  • Based on estimates for the next years, CRI will show a very strong growth in Earnings Per Share. The EPS will grow by 23.89% on average per year.
  • CRI is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -13.13% yearly.
EPS Next Y175.41%
EPS Next 2Y44.29%
EPS Next 3Y23.89%
EPS Next 5YN/A
Revenue Next Year-24.7%
Revenue Next 2Y-11.26%
Revenue Next 3Y-13.13%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CRI.PA Yearly Revenue VS EstimatesCRI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M
CRI.PA Yearly EPS VS EstimatesCRI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

4

4. CRI.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRI. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 9.95, which indicates a very decent valuation of CRI.
  • 93.33% of the companies in the same industry are more expensive than CRI, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of CRI to the average of the S&P500 Index (21.41), we can say CRI is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.95
CRI.PA Price Earnings VS Forward Price EarningsCRI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • 60.00% of the companies in the same industry are cheaper than CRI, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.75
CRI.PA Per share dataCRI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • CRI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CRI's earnings are expected to grow with 23.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.29%
EPS Next 3Y23.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

1

5. CRI.PA Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 1.54%, CRI has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 3.08, CRI's dividend is way lower than its industry peers. On top of this 80.00% of the companies listed in the same industry pay a better dividend than CRI!
  • CRI's Dividend Yield is comparable with the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 1.54%

5.2 History

  • The dividend of CRI decreases each year by -14.15%.
Dividend Growth(5Y)-14.15%
Div Incr Years1
Div Non Decr Years1
CRI.PA Yearly Dividends per shareCRI.PA Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2025 2026 0.5 1 1.5

5.3 Sustainability

  • The earnings of CRI are negative and hence is the payout ratio. CRI will probably not be able to sustain this dividend level.
DP-12.08%
EPS Next 2Y44.29%
EPS Next 3Y23.89%
CRI.PA Yearly Income VS Free CF VS DividendCRI.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

More info and screens

Find the best dividend stocksShow peers with best dividend

CRI.PA Fundamentals: All Metrics, Ratios and Statistics

COMPAGNIE CHARGEURS INVEST

EPA:CRI (4/30/2026, 7:00:00 PM)

8.44

-0.22 (-2.54%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryIndustrial Conglomerates
Industry Strength19.59
Industry Growth22
Earnings (Last)03-19
Earnings (Next)N/A
Inst Owners4.65%
Inst Owner ChangeN/A
Ins Owners64.2%
Ins Owner ChangeN/A
Market Cap210.07M
Revenue(TTM)419.70M
Net Income(TTM)-24.00M
Analysts74.29
Price Target12.07 (43.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.54%
Yearly Dividend0.12
Dividend Growth(5Y)-14.15%
DP-12.08%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.74%
PT rev (3m)4.41%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)5.66%
EPS NY rev (3m)11.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-31.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.95
P/S 0.5
P/FCF N/A
P/OCF 9.73
P/B 0.86
P/tB 11.36
EV/EBITDA 17.75
EPS(TTM)-0.99
EYN/A
EPS(NY)0.85
Fwd EY10.05%
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)0.87
OCFY10.28%
SpS16.86
BVpS9.77
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -2.49%
ROE -9.87%
ROCE 0.36%
ROIC 0.26%
ROICexc 0.31%
ROICexgc 0.48%
OM 0.64%
PM (TTM) N/A
GM 29.62%
FCFM N/A
ROA(3y)-0.61%
ROA(5y)0.79%
ROE(3y)-2.6%
ROE(5y)2.31%
ROIC(3y)2.15%
ROIC(5y)3.55%
ROICexc(3y)2.55%
ROICexc(5y)4.64%
ROICexgc(3y)5.43%
ROICexgc(5y)10.56%
ROCE(3y)2.94%
ROCE(5y)4.87%
ROICexgc growth 3Y-70.67%
ROICexgc growth 5Y-55.68%
ROICexc growth 3Y-65.68%
ROICexc growth 5Y-52.17%
OM growth 3Y-54%
OM growth 5Y-40.23%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.99%
GM growth 5Y2.14%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 1.56
Debt/FCF N/A
Debt/EBITDA 12.39
Cap/Depr 112.9%
Cap/Sales 7.51%
Interest Coverage 250
Cash Conversion 70.59%
Profit Quality N/A
Current Ratio 2.42
Quick Ratio 2.07
Altman-Z 0.98
F-Score5
WACC6.29%
ROIC/WACC0.04
Cap/Depr(3y)84.29%
Cap/Depr(5y)67.14%
Cap/Sales(3y)5.02%
Cap/Sales(5y)3.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-431.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-247.73%
EPS Next Y175.41%
EPS Next 2Y44.29%
EPS Next 3Y23.89%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.94%
Revenue growth 3Y-17%
Revenue growth 5Y-12.58%
Sales Q2Q%-18.24%
Revenue Next Year-24.7%
Revenue Next 2Y-11.26%
Revenue Next 3Y-13.13%
Revenue Next 5YN/A
EBIT growth 1Y-91.48%
EBIT growth 3Y-61.82%
EBIT growth 5Y-47.75%
EBIT Next Year38.24%
EBIT Next 3Y5.57%
EBIT Next 5YN/A
FCF growth 1Y-134.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.46%
OCF growth 3YN/A
OCF growth 5Y-21.62%

COMPAGNIE CHARGEURS INVEST / CRI.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of COMPAGNIE CHARGEURS INVEST (CRI.PA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRI.PA.


What is the valuation status for CRI stock?

ChartMill assigns a valuation rating of 4 / 10 to COMPAGNIE CHARGEURS INVEST (CRI.PA). This can be considered as Fairly Valued.


How profitable is COMPAGNIE CHARGEURS INVEST (CRI.PA) stock?

COMPAGNIE CHARGEURS INVEST (CRI.PA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for COMPAGNIE CHARGEURS INVEST?

The Earnings per Share (EPS) of COMPAGNIE CHARGEURS INVEST (CRI.PA) is expected to grow by 175.41% in the next year.